Taris Biomedical has gone back to the venture well as the biotech startup launches a midstage study of its lead candidate against bladder pain. The Lexington, MA-based company found support for its latest financing from previous backers at Flybridge Capital Partners, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
Our readers hunger for context and analysis of major developments in the industry. We work hard to deliver such insights in all of our daily reports. Yet we aim to go deeper into stories with additional feature articles and special reports.
T2 Biosystems pulled in a whopping $40 million Series E funding round to support clinical testing and a commercial launch of the company's Candida infection rapid diagnostic assay.
Living Proof has another $30 million in venture cash to get commercialization work in gear, while bankrolling some fresh efforts on the scientific side of the hair care venture.
When it comes to drug delivery, it's hard these days to overlook the buzzing field of nanoengineering. Highly targeted nanoparticles are on the cutting edge of the growing field, and according to BIND Biosciences' Jeff Hrkach, there are big things in store for the tiny drug carriers.
Bind Biosciences has landed an $8.7 million chunk of a planned $20 million raise designed to fuel the biotech's midstage study of its lead cancer drug.
Who in this business hasn't seen billions incinerated in pursuit of sheer folly? Influential today is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. And intelligent research strategies are far more rare than we acknowledge. You'll find some here in our second annual report on the 25 most influential people in the industry (find last year's report here ). Check out the list >>
In a major coup for a startup that only turns 6 years old this year, BIND Biosciences has signed a global and exclusive agreement with Amgen, the world's largest independent biotechnology company.
For the first time BIND Biosciences has found a large drugmaker to commit major money to collaborate on a drug with its nanomedicine platform.
T2 Biosystems will launch a pivotal trial for the company's rapid diagnostic assay for Candida infections by early February.